Clonazepam NDC 62135-770

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-770Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0770Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-770-90	62135077090	90 TABLET in 1 BOTTLE (62135-770-90)Marketed from Oct 29, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Clonazepam
Generic name (nonproprietary): clonazepam
Active ingredients: Clonazepam — 1 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Chartwell RX, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 074925
Marketing start: Sep 30, 1997
Listing expires: Dec 31, 2026
DEA schedule: CIV
Other FDA classes: Benzodiazepines (Chemical structure)
Identifiers: Product ID 62135-770_09184e1a-1808-d656-e063-6294a90aa6f8SPL ID 09184e1a-1808-d656-e063-6294a90aa6f8SPL set ID 7b543f77-4388-4227-942f-7933f200b3a5RxCUI 197527, 197528, 197529UNII 5PE9FDE8GBUPC 0362135770907, 0362135769901, 0362135771904
Pharmacologic class: Benzodiazepine

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135077090 followed by a unit qualifier and the quantity

Package 62135-0770-90. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 1, 2023. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Seizure Disorders Clonazepam tablets, are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam tablets, may be useful. Some loss of effect may occur during the course of clonazepam treatment (see PRECAUTIONS: Loss of Effect ). Panic Disorder Clonazepam tablets, are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-V. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, w…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 074925

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 074925
Product	Strength	Form · route	Labeler	Product NDC
Clonazepam	Clonazepam .5 mg/1	TabletOral	Chartwell RX, LLC	62135-769
Clonazepam	Clonazepam 2 mg/1	TabletOral	Chartwell RX, LLC	62135-771